Press Releases Glaukos Corporation

Stocks

GKOS

US3773221029

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe BZX Other stock markets 12:25:52 2026-06-11 pm EDT			5-day change	1st Jan Change
124.54 ^USD	+1.67%		+2.56%	+10.53%

May. 14	Glaukos Insider Sold Shares Worth $675,000, According to a Recent SEC Filing	MT
May. 05	Glaukos Insider Sold Shares Worth $2,809,508, According to a Recent SEC Filing	MT

Press Releases

May. 12	Glaukos Announces Participation in Upcoming Investor Conferences	BU
May. 04	Glaukos : Investor Presentation May 2026	PU
Apr. 29	Glaukos: Q1 Earnings Snapshot	AQ
Apr. 29	Glaukos : First Quarter 2026 Quarterly Summary	PU
Apr. 29	Glaukos : First Quarter 2026 GAAP to Non-GAAP Recs	PU
Apr. 29	Glaukos Announces First Quarter 2026 Financial Results	BU
Apr. 16	Glaukos Announces the Release of its 2025 Sustainability Report	BU
Apr. 15	Glaukos Receives Permanent J-code for Epioxa™	BU
Apr. 08	Glaukos to Release First Quarter 2026 Financial Results after Market Close on April 29	BU
Apr. 06	Glaukos to Present Multiple Scientific Abstracts at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting	BU
Mar. 20	Glaukos Announces Commercial Availability of Epioxa, a Transformative Innovation in Interventional Keratoconus Care	AQ
Mar. 19	Glaukos Announces Commercial Availability of Epioxa™, a Transformative Innovation in Interventional Keratoconus Care	BU
Mar. 02	Glaukos : Investor Presentation March 2026	PU
Feb. 23	Glaukos : Annual Report for Fiscal Year Ending December 31, 2025 (Form 10-K)	PU
Feb. 17	Glaukos: Q4 Earnings Snapshot	AQ
Feb. 17	Glaukos : Fourth Quarter 2025 Quarterly Summary	PU
Feb. 17	Glaukos Announces Fourth Quarter and Full Year 2025 Financial Results	BU
Jan. 29	Glaukos Announces US FDA Approval of NDA Supplement Allowing for Re-Administration of iDose TR	AQ
Jan. 28	Glaukos Announces US FDA Approval of NDA Supplement Allowing for Re-Administration of iDose® TR	BU
Jan. 20	Glaukos to Release Fourth Quarter and Full Year 2025 Financial Results after Market Close on February 17	BU
Jan. 13	Glaukos : Investor Presentation January 2026	PU
Jan. 13	Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Sales and Reaffirms 2026 Revenue Guidance	BU
Dec. 16	Glaukos Announces Participation in J.P. Morgan Healthcare Conference	BU
Nov. 10	Glaukos : Investor Presentation November 2025	PU
Nov. 03	Glaukos Announces Participation in Upcoming Investor Conferences	BU